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The intestine mediates a delicate balance between tolerogenic and inflammatory immune
responses. The continuous pathogen encounter might also augment immune cell
responses contributing to complications observed upon intestinal transplantation (ITx).
We thus hypothesized that ITx patients show persistent signs of immune cell activation
affecting both the adaptive and innate immune cell compartment. Information on the
impact of intestinal grafts on immune cell composition, however, especially in the
long-term is sparse. We here assessed activated and differentiated adaptive and innate
immune subsets according to time, previous experience of cellular or antibody-mediated
rejections or type of transplant after ITx applying multi-parametric flow cytometry, gene
expression, serum cytokine and chemokine profiling. ITx patients showed an increase
in CD16 expressing monocytes and myeloid dendritic cells (DCs) compared to healthy
controls. This was even detectable in patients who were transplanted more than 10 years
ago. Also, conventional CD4+ and CD8+ T cells showed persistent signs of activation
counterbalanced by increased activated CCR4+ regulatory T cells. Patients with previous
cellular rejections had even higher proportions of CD16+ monocytes and DCs, whereas
transplanting higher donor mass with multi-visceral grafts was associated with increased
T cell activation. The persistent inflammation and innate immune cell activation might
contribute to unsatisfactory results after ITx.
Keywords: intestinal transplantation, T cells, Myeloid cells, flow cytometry, gene expression, cytokines,
epigenetics
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INTRODUCTION
Intestinal transplantation is an accepted therapeutic option
for patients with live-threatening complications upon
home parenteral nutrition after intestinal failure (1). The
intestine guarantees nutrient absorption but also serves as a
protective barrier with contact to commensals and pathogens.
Consequently, an efficient communication between local and
infiltrating immune cells is needed to maintain a healthy
balance between inflammatory responses preventing pathogen
invasion and tolerogenic responses against food antigens and
commensals (2). Therefore, the small intestine contains various
lymphoid structures and thus compared to other transplanted
solid organs has a far higher number of donor immune cells
(3). Thus, transplantation of an allogeneic intestine represents
a major challenge for this tightly controlled balance and ITx
patients are prone to more complications than other solid
organ transplant recipients. In addition to a higher rate of acute
rejection episodes, ITx patients suffer from invasive infections
and GvHD (4, 5). Furthermore, the incidence of antibody-
mediated humoral rejections is much higher as compared to
other transplantations (6–8).
Due to a lack of serum markers indicating an impaired
intestinal graft function, diagnosis of rejection episodes
requires a combination of clinical, endoscopic examinations,
histological assessment of biopsies, and screening for serum
donor-specific HLA or non-HLA antibodies (6, 7, 9–13).
However, interventions to obtain biopsies are associated with
complications and may also trigger injury-related immune
reactions. Furthermore, histological discrimination between
rejections and viral infections remains challenging warranting
the search for novel and particular non-invasive markers.
Indeed, several studies revealed increased numbers or
mediators of intragraft and peripheral Th1 and Th17 cells as well
as CD8+ cytotoxic T cells prior or during rejection (14–21).
Comparatively little is known about the impact on the innate
immune cell compartment. Gupta et al. identified a higher
myeloid to plasmacytoid DCs balance in pediatric ITx patients
with early acute cellular rejection (22).
So far, only individual aspects of the immune system have
been studied but no broader assessment of the immune cell
composition was performed. In addition, changes in B cell
subsets were not analyzed although intestinal grafts contain large
numbers of B cells. Also, long-term effects were not studied
and no discrimination between cellular and humoral rejections
was made.
The intestinal immune compartment especially upon
inflammatory challenges is in constant interaction with other
immune compartments such as the blood or the liver (23–
25). Thus, it appears likely, that in a situation of permanent
interaction between self and foreign immune cells major and
Abbreviations: DCs, dendritics cells; EDTA, ethylenediaminetetraacetate; Foxp3,
forkhead box P3; GvHD, graft vs. host disease; HLA, human leukocyte antigen;
ITx, intestinal transplantation; MMF, mycophenolate mofetil; NK, natural killer
cells; Th1, T helper 1 cells; Th2, T helper 2 c ells; Th17, T helper 17 cells; Th22, T
helper 22 cells; Treg, T regulatory cells; TSDR, Treg specific demethylation region.
long-lasting systemic changes in immune cell composition
can be observed. Analyzing which subsets are affected will not
only provide a more detailed understanding of the interplay of
innate and adaptive immune cells and thus immune responses
following intestinal transplantation but also give novel insights
into the intestine physiology in general.
Consequently, the present study assessed whether upon
intestinal transplantation a long-lasting increase in inflammatory
differentiated innate and activated adaptive immune cell subsets
can be detected. We also investigated immune cell composition
in association with organ type or clinical events such as
cellular or antibody-mediated rejections. We show that intestinal
transplantation is associated with a long-lasting increase in CD16
expressing myeloid mononuclear cells. Conventional T cells
showed persistent signs of activation and differentiation, which
was counterbalanced by increased levels of activated regulatory
T cells. Patients who had experienced cellular rejections showed
even higher proportions of CD16+ monocytes and myeloid
DCs. In contrast, the type of organ and thus donor mass being
transplanted was associated with T cell activation.
MATERIALS AND METHODS
Study Populations
Samples from 11 isolated intestinal (i-ITx) and 10 multivisceral
transplanted (MVTx) ITx patients (Table 1, between April
2014 and February 2015) and 17 healthy controls of similar
age range and gender were collected. We collected three to
eight consecutive samples per ITx patient and median results
were calculated.
Itx patients received induction therapy of thymoglobulin
(Thymoglobulin R©, Genzyme, Cambridge, Mass., USA; 7.5
mg/kg BW total dose) and one dose of infliximab (Remicade R©,
Centocor Inc., Essex Pharma GmbH; 5 mg/kg BW). Maintenance
immunosuppressive treatment consisted of tacrolimus and
rapamycin (sirolimus/everolimus) or MMF (Cellcept R©,
Hoffmann-LaRoche, Switzerland).
Patients were categorized (i) according to time after
transplantation (ITx1 ≥ 10 years, ITx2 = 4–10 years, ITx3 0–4
years) or (ii) according to occurrence of rejections (no AR = no
rejection episodes; AR1 = patients with one or several humoral
or mixed cellular and humoral rejections; AR2 = patients with
one or several cellular rejections). Rejection was defined based
on a combination of clinical symptoms and biopsy assessment
according to established histological rejection criteria (10, 11).
In addition, for diagnosis of humoral rejections assessment of
anti-donor HLA antibodies and C4d-staining was performed as
previously described (7). Importantly, the tacrolimus trough level
was not different between patient groups studied.
All participants gave their written consent to take part
in this study authorized by the local ethics committee
(Ethikkommission der Charité—Universitätsmedizin Berlin,
EA2/044/08 & EA2-020-14).
Flow Cytometry
Blood samples were stained within 4 h and analyzed by
flow cytometry according to the protocol of the ONE-Study
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Consortium (27, 28). In addition, we included a chemokine
receptor panel for categorization of T helper and Treg cell subsets
(panel 6, see Supplementary Figure 1 for gating strategy).
All fluorochrome-conjugated antibodies used are listed within
Supplementary Table 1. In general, 100 µl EDTA blood were
directly stained with prepared panel antibody mixes and
incubated before lysing erythrocytes with lyse-fix solution
composed of Versa LyseTM and IOTest R© Fixative Solution
(Beckman Coulter GmbH). For the Treg panel (panel 7) 50 µl
EDTA blood were used and additionally stained for intracellular
expression of Foxp3 using the PerFix-nc Kit (Beckman Coulter),
whereas for the B cell panel (panel 4) 300 µl EDTA blood
was first lysed with Red Blood Cell Lysis Solution (Miltenyi
Biotec GmbH) prior to antibody staining. The dendritic cell
panel 5 was prepared twice and combined after staining. Samples
were measured on a 10 color Navios flow cytometer (Beckman
Coulter). Calibration with “Flow-Set Pro Beads” and “Flow
Check Pro Beads” (both Beckman Coulter) was performed daily.
T Cell Chimerism Analysis
PBMC were isolated at room temperature by density gradient
centrifugation (Biocoll, Biochrom, Berlin, Germany) of
heparinized blood diluted 1:2 in Phosphate-Buffered Saline
(PBS, Gibco, Thermo Fisher Scientific, Paisley, UK). Cell number
was determined using a hemocytometer. Isolated PBMC were
cryopreserved until further use. Cryopreserved PBMCs of
transplanted patients were first incubated with 3,2 mg/ml human
immunoglobulin (Beriglobin, CSL Behring, Germany) for 5min
to block Fc receptors and then stained with anti-TCRαβ-PE, anti-
CD4-APC and anti-HLA-DR-ECD (see Supplementary Table 1
for additional information about the antibodies). After washing,
cells were stained with 4′,6-diamidino-2-phenylindole (DAPI)
and sorted on a FACSAria II (BD Biosciences, Heidelberg,
Germany) into DAPI−TCRαβ+CD4+HLA-DR− or –HLA-DR+
fractions. Please see Supplementary Figure 4 for gating strategy.
Chimerism analyses were based on the discrimination of
donor and recipient alleles on short tandem repeats using PCR
with fluorescence-labeled primers. DNA was extracted using
a standard DNA extraction method (QIA-Amp; QIAGEN),
as recommended by the manufacturer. For quantitative
chimerism investigation we used AmpFlSTR R© Identifier R©
PCR Amplification KIT (Applied Biosystems) which contains
fluorescent-labeled primer pairs for simultaneous amplification
of 16 different loci each. For quantification of chimerism, the
areas under the curves were calculated using Genemapper





Blood samples were collected in Tempus Blood RNA Tubes
(Thermo Fisher Scientific, Schwerte, Germany) and RNA was
isolated using the MagMAXTM for Stabilized Blood Tubes RNA
Isolation Kit (Thermo Fisher Scientific). Up to 1,000 ng RNA
were transcribed into cDNA using the QuantiTect Reverse
Transcription Kit (Qiagen, Hilden, Germany). Gene expression
was measured using TaqMan Gene Expression Assays (Thermo
Fisher Scientific, see Supplementary Table 2), microfluidic cards
and TaqMan Universal Master Mix (Thermo Fisher Scientific)
on the ViiA7 Real Time PCR System (Thermo Fisher Scientific).
Reactions were run in duplicates using 384-well microfluific
Custom TaqMan R© Array Cards. Data were analyzed with ViiA7
Software v 1.2.2. Gene expression was calculated relative to
median expression of three reference genes [Hypoxanthine-
guanine phosphoribosyltransferase (HPRT), beta-2-microglobulin
(B2M) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH)]
using the 2−11Ct method.
Genomic DNA was isolated from EDTA blood using the
QIAamp DNA Mini Kit (Qiagen). Up to 2 µg DNA were
used for bisulfite treatment (EpiTect, Qiagen). Real-time PCR
was done in a final reaction volume of 20 µl with 10 µl
FastStart Universal Probe Master (ROX, Roche Diagnostics,
Mannheim, Germany), 100 ng Lamda DNA (NEB, Frankfurt
a.M., Germany), 5 pmol methylation or non-methylation specific
probe, 30 pmol methylation or non-methylation specific primers
and at least 15 ng bisulfite-treated DNA or plasmid standard
(all Epiontis GmbH, Berlin, Germany). Samples were analyzed
in triplicates on an ABI 7500 Cycler (Thermo Fisher Scientific).
The percentage of CD4+ T cells with demethylated TSDR
was calculated by division of non-methylated by total genomic
FoxP3 copy-number and normalization to the proportion of total
CD3+CD4+ T cells as determined by flow cytometry.
Luminex Measurement of Cytokines and
Chemokines
Samples were prepared with Milliplex R© MAP Kit (Merck KGaA,
Darmstadt, Germany) according to manufacturer’s protocol. The
Bio Plex R© 200 Systems (Luminex, Bio-Rad Laboratories GmbH)
was validated every 30 days with the Bio-Plex R© Validation Kit
(Bio-Rad Laboratories GmbH) and was calibrated every day with
Bio-Plex R© Calibration Kit (Bio-Rad Laboratories GmbH).
Data Analyses and Statistics
Analysis of flow cytometry data was done with Kaluza version
1.2 (Beckman Coulter). To calculate absolute cell numbers of all
reported immune cell subsets, leucocyte cell count was obtained
from the clinical chemistry and related to the CD45+ count
within each panel. The corresponding proportions of all reported
immune cell subsets were calculated in Excel. In case of multiple
samples from ITx patients a median was calculated. Differences
in subset proportions and absolute cell counts between healthy
donors and ITx patients as well as according to time post-
transplant, rejection or organ type were analyzed with Kruskal-
Wallis-Test and a Conover post-hoc test. Results were considered
as significant when a p < 0.05 was reached. P-values were not
adjusted for multiple testing because of an explorative approach.
R was used for generating a heatmap representation of
the mean-centered and sigma-normalized data selected for
parameters with a p< 0.05 in Kruskal-Wallis-Test, using pairwise
euclidean distances and Ward’s minimum variance method for
hierarchical clustering.
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Differences in subset proportions and absolute cell counts
between healthy donors and ITx patients as well as according to
time post-transplant, rejection or organ type were analyzed with
Kruskal-Wallis-Test and a Conover post-hoc test. Results were
considered as significant when a p< 0.05 was reached.
RESULTS
To investigate whether indeed intestinal transplantation is
accompanied by persistent signs of innate and adaptive immune
cell activation, we performed multi-parametric profiling of
peripheral blood immune cells. From ITx patients three to eight
consecutive samples within the observation period were collected
and analyzed. The individual immune cell composition was very
stable within the observation period (Supplementary Figure 2).
From the obtained data median values were calculated.
We assessed the impact of intestinal transplants according to
three main hypotheses:
1) The high donor immune cell number and pathogen
encounter in ITx grafts triggers persistent immune
cell activation resulting in an elevation of activated or
inflammatory T and innate immune cell subsets compared to
healthy controls.
2) ITx patients show a very slow normalization of immune cell
composition normalize over time after transplantation. This
was investigated by dividing the transplant patients into three
groups: (i) long-term >10 years after transplantation (ITx 1),
(ii) mid-term 4–10 years (ITx 2), and (iii) short-term 0–4
years (ITx 3).
3) Previous episodes of acute humoral/mixed rejection (AR 1)
or acute cellular rejections (AR 2) are associated with further
increase of activated or inflammatory immune cell subsets
compared to patients with no rejections (no AR).
Increase of CD16+ Monocytes and DCs in
Blood of ITx Patients
First, we investigated differences in proportions and absolute
numbers of innate immune cells including granulocytes,
monocytes, DCs, NK cells, and their major subsets (Figures 1, 2
and Supplementary Tables 3, 4). We could not detect differences
in granulocytes between samples from healthy controls and
transplant patients (Figure 1A). However, there was a significant
decrease in absolute granulocyte numbers in samples of patients
who had experienced cellular rejections (AR2, Figure 1B and
Supplementary Tables 3, 4). Total monocytes were increased in
long-term transplant patients (Figure 1A). The proportions and
absolute numbers of the CD14highCD16+ subset were increased
in patient samples especially early after transplantation and
proportions of both CD16 expressing monocytes subsets were
higher in patients experiencing cellular rejections (Figure 1C and
Supplementary Tables 3, 4).
Although samples from transplant patients did not contain
more DCs, they were higher in patients with previous cellular
rejections (Figure 1B). We also observed an altered balance
between plasmacytoid and myeloid DCs in patients (Figure 1A)
resulting from an increase in the CD16+ subset (Figure 1D). This
increase of CD16+ myeloid DCs was especially prominent for
patients who had cellular rejections.
There was a trend toward higher proportions of NK cells
early after transplantation (ITx3, Figure 2A), mainly due to
an expansion of CD56high NK cells normalizing 10 years after
transplantation (ITx1). Increase of total CD56+ NK cells was
seen in stable patients without rejection episodes (no AR,
Figure 2B), who had similarly low proportions of CD56high NK
cells compared to healthy controls.
Altogether, ITx patients have major alterations in their
systemic innate immune compartment either occurring
independently from clinical events or associated with rejections.
Changes related to rejections were independent of time since
last rejection episode (data not shown). The organ type being
transplanted did no influence composition of innate immune
cell subsets (Supplementary Figure 3A).
Increased Proportions of Activated and
Differentiated Conventional Recipient T
Cell Subsets Also in Patients With No
Rejections
T cells are known to play a major role in controlling anti-
donor immune responses and eliciting rejections. Therefore,
changes in composition of helper and cytotoxic T cells and their
activated subsets were assessed. CD4+ (TCRαβ+) T helper cell
proportions and absolute numbers were significantly lower in
transplant patient samples especially early after transplantation
(ITx2 & 3, Figure 3A and Supplementary Tables 3, 4). This
was independent of rejections (Figure 3B). Furthermore, a
large proportion of the T helper cells showed signs of acute
and chronic activation e.g., HLA-DR and CD57 expression,
respectively (Figure 3A). Consistently, transplant patients
showed a reduction of naïve T cells (Figure 3C) and strong
increase of CD27− late stage effector like T cells (Figure 4A).
Although these changes were especially apparent early after
transplantation, they were still detectable in patients who had
been transplanted more than 10 years ago (ITx1). Similar
observations were made for CD8+ cytotoxic T cell subsets
(Figures 3D, 4A). Much to our surprise, the increase in activated
and differentiated T cell subsets was not significantly higher
in patients who had experienced rejections Figures 3B,C,E,F
and 4B. However, we detected higher proportions of HLA-
DR+, CD57+, or CD27− T cells in patients who received a
multi-visceral transplant (Supplementary Figure 3B). It has
been previously shown that ITx patients especially early after
transplantation display T cell donor chimerism (29). Therefore,
we investigated whether the activated T cells are of donor or
recipient origin. We have FACS-sorted CD4+ T cells from
frozen PBMCs of nine different ITx patients (three of each ITx
group, mixed balance of isolated and multivisceral transplanted
patients) into HLA-DR+ and HLA-DR− proportions (see also
new Supplementary Figure 4). Afterwards, DNA was isolated
and the degree of chimerism determined by PCR utilizing
fluorescence-labeled primers which discriminate between donor
and recipient alleles. Interestingly, in none of the samples,
neither in HLA-DR+ activated nor in HLA-DR− non-activated
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FIGURE 1 | Absolute cell numbers and proportions of indicated innate immune cell subsets in whole blood samples from ITx patients and healthy controls (HCs) were
analyzed by flow cytometry. (A) Boxplots showing the median and minimum to maximum of results separating the ITx patients according to time after transplantation:
0–4 years (ITx 3, n = 7), 4–10 years (ITx 2, n = 8), and >10 years (ITx 1, n = 6) post-transplantation. The following parameters/cell populations are shown: absolute
numbers of granulocytes (identified as CD45lowSSChigh) in cells/nl, % of granulocytes of total CD45+ leukocytes, % of CD14+ monocytes of total CD45+
leukocytes, % LIN−HLA-DR+ dendritic cells of total CD45+ leukocytes, % CD11c−CD123+ plasmacytoid dendritic cells of dendritic cells, and CD11c+ myeloid
dendritic cells of dendritic cells. (B) Boxplots showing the median and minimum to maximum of results separating the ITx patients according to clinical rejection
episodes: no rejection (no AR, n = 7), acute humoral/mixed rejection (AR 1, n = 7), and acute cellular rejection (AR 2, n = 5). (C) Mean proportions of monocyte
subsets (1 = CD14+CD16high, 2 = CD14highCD16+, 3 = CD14highCD16−) in ITx patients separated according to time after transplantation or occurrence of
rejections. (D) Mean proportions of myeloid dendritic cell subsets (1 = rest, 2 = Clec9+, 3 = CD1c+, 4 = CD16+) in ITx patients separated according to time after
transplantation or occurrence of rejections. Statistical analysis was done using a Kruskal-Wallis-Test and Conover post-hoc test. *p < 0.05, **p < 0.01.
cells, we could detect donor alleles (0% donor chimerism in
all samples).
Thus, CD4+ and CD8+ systemic recipient T cell compartment
of ITx patients is heavily altered showing signs of constant T cell
activation mostly dependent on donor mass being transferred.
Increase in Proportions of Chemokine
Receptor Expressing Subsets of
Conventional T Helper and Regulatory T
Cells
With intestinal transplantation representing a major
inflammatory event it might trigger upregulation of chemokine
receptor expression enhancing the homing potential of
circulating T cells. Investigation of chemokine receptor
expression was done for regulatory and conventional
CD4+ T cells. Proportions but not absolute numbers
of CD4+CD25++Foxp3+ regulatory T cells (Tregs) were
significantly higher in transplant patients even 10 years after
transplantation compared to healthy controls (Figure 5A and
Supplementary Tables 3, 4). In accordance, the percentage of
CD4+ T cells with a demethylation of the TSDR determining
stable Foxp3 expressing Tregs were higher in ITx patients
but independent of rejections (Supplementary Figures 5A,C).
However, we did not observe differences in Foxp3 mRNA
expression (Supplementary Figures 5B,D).
Nearly all of the systemic Tregs showed an activated CCR4
expressing phenotype (30). Furthermore, the majority displayed
CCR6 co-expression (Figure 5B).
We also assessed proportions and absolute numbers




mixed Th1/Th2-like (CCR4+CCR6−CXCR3+CCR10−), and
pathogenic Th17-like (CCR4−CCR6+CXCR3+CCR10−)
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FIGURE 2 | Comparative analysis of NK cell subsets. Boxplots showing the
median and minimum to maximum of proportions of total NK cells (A,B),
CD56high NK cells (A,B) in whole blood samples from patients according to
time post-transplant (A: ITx = 0–4 years, n = 7; ITx = 4–10 years, n = 8; ITx >
10 years, n = 6) or occurrence of rejections (B: no AR = no rejection, n = 7;
AR1 = humoral/mixed rejection, n = 7; and AR2 = acute cellular rejection, n =
5) and healthy controls (HCs). Statistical analysis was done using a
Kruskal-Wallis-Test and Conover post-hoc test. *p < 0.05.
chemokine receptor expression profile (Figure 5C and
Supplementary Tables 3, 4) (31, 32). CCR10 expressing T
cells represented only a minor fraction of conventional CD4+ T
cells. Therefore, we did not capture CCR10 expressing subsets.
We did not detect differences in Th1-like T helper cells neither
when comparing transplant patients and healthy controls nor
according to rejections. Similarly, Th17-like cells occurred at very
low numbers and were not different between groups. In contrast,
Th2-like cells seem to accumulate over time in ITx patients
(ITx1). We also observed a significant increase in proportions
of populations expressing several chemokine receptors such
as Th22-like, pathogenic Th17-like or Th1/Th2-like cells in
transplant patients (Figure 5C).
Thus, ITx patients are characterized by higher proportions
of chemokine receptor expressing regulatory and conventional
CD4+ T cells regardless whether they experienced rejections
or not.
High Systemic Chemokine and Cytokine
Levels Even in Stable Transplant Patients
As we did detect increased proportions of chemokine receptor
expressing T helper cells in ITx patients, we also investigated
serum chemokine and cytokine concentrations.
Concentrations of chemokines attracting T cells and
macrophages such as CXC3CL1, CXCL10, CCL2, CCL7,
CCL3 as well as cytokines released by T helper subsets such
as Interleukin (IL)-2, IL-4, IL-5, IL-10, IL-17A, or interferon
gamma (IFN-γ) were determined. Serum samples from patients
early after transplantation (ITx3) contained more CXC3CL1 and
CXCL10 compared to those from healthy controls (Figure 6A).
Furthermore, cytokines typically produced by Th2 cells such
as IL-4 and IL-5 were significantly elevated also in long-
term transplant patients (Figure 6A). Although Th1 (IL-2,
IFN-g) and Th17 cytokines (IL-17A) showed a tendency to
be increased in serum samples of transplant patients, this
did not reach significance. We only detected a tendency
toward higher fractalkine, IL-2, and IL-4 concentrations
in serum samples of patients with cellular rejections
(Supplementary Figures 6A,B).
Altogether, we detected high systemic T cell attracting
chemokines and Th2 cytokines in ITx patients even long-term
after transplantation and independent of rejections.
Cluster Analysis of Parameters
Contributing to Patient Group Separation
To obtain a better overview of parameters contributing to patient
group separation according to time and rejection after intestinal
transplantation we performed a cluster analysis of all parameters
which had an unadjusted p< 0.05 comparing healthy controls to
early (ITx3), mid-term (ITx2), and long-term (ITx1) transplant
patients (Figure 6B) or comparing patients with regard to
occurrence of rejections (Figure 6C). We also included qRT-
PCR results of gene markers previously described to be highly
expressed in operational tolerant or acutely/chronically rejecting
kidney transplant recipients (Supplementary Table 5).
The heatmap shown in Figure 6B confirms, that nearly all ITx
patients are distinct to healthy controls. Populations contributing
mostly to the separation and being higher in ITx patients were
belonging to the B cell lineage (e.g., total B cells, naïve B
cells). Indeed, gene markers known to be highly expressed by
transitional and naïve B cells such as Membrane Spanning 4-
Domains A1 (MS4A1), CD79B, and T-Cell Leukemia/Lymphoma
1A (TCL1A) were enriched in samples from ITx patients.
Further populations and marker contributing to the separation
were CD16+ monocytes, CD56high NK cells, γδ+ T cells,
memory/activated/chemokine receptor expressing CD4+ T cell
subsets as well as IL-4.
In contrast, CD16− monocytes, CD56dim NK cells as well as
naïve/non-activated CD4+ and CD8+ T cell subsets were high in
healthy controls. A complete list of all cell populations or gene
markers contributing to the separation by being either higher
(upper main cluster) or reduced (lower main cluster) ITx patients
is provided within Supplementary Table 6.
As shown in Figure 6C significant differences in CD16
expressing monocytes and DCs as well as TLR5 expression
allowed separation of patients who never experienced rejection
episodes (no AR) or humoral rejections (AR1) from all patients
who had cellular rejections (AR2). However, separation of
patients with humoral rejections (AR1) from stable patients (no
AR) was not possible.
DISCUSSION
We have performed comprehensive assessment of the systemic
innate and adaptive immune system according to time, rejections
or organ type after intestinal transplantation. Our results revealed
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FIGURE 3 | Comparative analysis of αβ T cell memory differentiation and expression of activation markers measured by flow cytometry. Shown are proportions as
boxplots (median and minimum to maximum) of total, activated HLA-DR or CD57 expressing CD4+ (A,B) and CD8+ αβ T cells (D,E) as well as their
CD45RA+CCR7+ naïve (1, TN), CD45RA
−CCR7− central memory (2, TCM), CD45RA
−CCR7− effector memory (3, TEM), and CD45RA
+CCR7− terminal
differentiated effector memory (4, TEMRA ) subpopulations (C,F) measured in whole blood samples from intestinal transplant patients separated according to time
post-transplant (ITx = 0–4 years, n = 7; ITx=4–10 years, n = 8; ITx > 10 years, n = 6) or occurrence of rejections (no AR = no rejection, n = 7; AR1 = acute
humoral/mixed rejection, n = 7; and AR2 = acute cellular rejection, n = 5) and healthy controls. Statistical analysis was done using a Kruskal-Wallis-Test and Conover
post-hoc test. *p < 0.05, **p < 0.01, ***p < 0.001.
that ITx patient samples contained more CD16 expressing
monocytes and myeloid DCs independent of rejections. This
was detectable even 10 years after transplantation. Similarly,
we observed enhanced proportions of activated conventional
recipient T cells which showed a broad T helper cell chemokine
expression profile associated with constant high serum Th1,
Th2, and Th17 cytokine levels in comparison to healthy
control samples. This increase in activated T helper cells
was associated with the organ type being transplanted and
counterbalanced by enhanced proportions of activated regulatory
T cells. Furthermore, the persistent signs of T cell activation were
not related to pre-transplant sensitization as none of the patients
had DSA prior to transplantation (Table 1).
Cellular rejections induced an even more dramatic increase
in total DCs, CD16 expressing monocytes and DCs as well as
CD56high NK cells whereas proportions of total NK cells were
reduced. Together with reduced peripheral TLR5 expression
this pattern enabled clear separation of patients with previous
cellular rejection from stable patients and patients with humoral
rejections. Importantly this was not related to differences in IS
as tacrolimus trough level were not different between all three
patient groups.
Previous reports revealed increased proportions of myeloid
cells, monocytes and DCs, in pediatric ITx patients experiencing
acute rejections (22, 33). In our cohort CD16 expressing
monocytes and myeloid DCs were also highest in patients with
cellular rejections. Elevated proportions of CD16 expressing
monocytes have been observed in patients with ongoing
inflammation such as chronic kidney disease patients (CKD) and
are discussed to reflect endothelial damage (34).
In previous studies enhanced frequencies of donor-reactive
CD154+ activated memory T cells in rejecting patients have
been observed (14, 21). Our analysis revealed a general and
persistent high T cell activation, T helper cell differentiation and
memory T cell formation with no obvious differences according
to previous experience cellular or humoral rejection episodes
but rather donor mass being transplanted. The effect of antigen
mass is in accordance with other previous investigations (35).
Most of the samples from patients experiencing cellular or
humoral rejections were collected months or years after the
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FIGURE 4 | Analysis of T cell senescence and exhaustion markers. Boxplots of proportions (median and minimum to maximum) of CD27−, CD28− as well as PD1
expressing subpopulations of CD4+ and CD8+ T cells in whole blood patient samples and healthy control samples were determined by flow cytometry and plotted
according to time post-transplant (A: ITx = 0–4 years, n = 7; ITx = 4–10 years, n = 8; ITx > 10 years, n = 6) or occurrence of rejection episodes (B: no AR = no
rejection, n = 7; AR1 = acute humoral/mixed rejection, n = 7; and AR2 = acute cellular rejection, n = 5). Statistical analysis was done using a Kruskal-Wallis-Test and
Conover post-hoc test. *p < 0.05, **p < 0.01, ***p < 0.001.
FIGURE 5 | Regulatory T cells and conventional T helper subsets. (A) Proportions shown as boxplots (median and minimum to maximum) of total
CD4+CD25++Foxp3+ regulatory T cells in whole blood samples from patients and healthy controls displayed according to time after transplantation (left: ITx = 0–4
years, n = 7; ITx = 4–10 years, n = 8; ITx > 10 years, n = 6) or occurrence of rejections (right: no AR = no rejection, n = 7; AR1 = acute humoral/mixed rejection, n
= 7; and AR2 = acute cellular rejection, n = 5). (B) Overview on proportions of CCR4+ activated memory regulatory T cells and their co-expression of CCR6, CXCR3,
or CCR10 within whole blood patient samples and healthy control samples. (C) Proportions of CD25−/+ conventional T cells expressing CCR4, CCR6, or CXCR3
resembling a Th2, Th1, TH1/Th2, Th17, pathogenic Th17 or Th22-like phenotype in patient and healthy control samples. Statistical analysis was done using a
Kruskal-Wallis-Test and Conover post-hoc test. *p < 0.05, **p < 0.01, ***p < 0.001.
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FIGURE 6 | Serum cytokines, chemokines as well as heatmaps summarizing differences according to time and rejection. (A) Chemokine and cytokine levels in serum
samples of transplant patients (Tx, n = 18) and healthy controls (HCs, n = 4) were measured using the luminex technology. Transplant patients were categorized
according to time after transplantation (ITx1: n = 6, ITx2: n = 8, ITx3: n = 3). Statistical analysis was done using a Kruskal-Wallis-Test and Conover post-hoc test.
*p < 0.05 **p < 0.01. (B,C) heatmaps summarizing parameters that differ according to time and rejection (euclidean distance, unadjusted p < 0.01). Blue boxes =
low values, red boxes = high values. (B) Comparison of ITx patients with HCs. ITx were divided according to time since Tx in long- (ITx 1: >10 years), mid- (ITx 2:
4–10 years), and short-term (ITx 3: 0–4 years). Clusters (dashed boxes) are comprised mainly of activated/differentiated/pathogenic (red) and naive/non-activated
(black) immune subsets. (C) Analysis of acute cellular (AR 2), humoral/mixed (AR 1) and no rejection (no AR) in ITx patients. Complete list of all parameters that differ
according to time and rejection after transplantation are given in Supplementary Table 6.
last rejection episode, which might explain the discrepancies.
Also, our main aim was not to identify predictive biomarkers
of or diagnose rejection, but to determine how intestinal
transplantation including accompanying clinical events such
as rejections affects systemic immune cell composition and
activation. Surprisingly and in contrast to previous studies that
revealed a high degree of donor T cell chimerism especially
early after transplantation and in patients receivingmulti-visceral
transplants (29, 36, 37), we could not detect donor alleles in
peripheral blood CD4+ T helper cells, neither in the activated
HLA-DR+ nor in the non-activated HLA-DR− subpopulation.
Thus, the constant high proportions of activated T cells are not
a sign of persistent chimerism.
Increased pDCs have been associated with development
of tolerance upon e.g., liver transplantation (38, 39). Thus,
the persistently low pDC/mDC ratio and high proportion
of the inflammatory CD16 expressing monocytes and DCs
detected in our patient cohort might be an indication of
constant inflammation.
We detected a significantly decreased absolute number and
proportions of granulocytes in samples of patients with a
previous cellular rejection. Indeed, intragraft sequestration of
neutrophils has been described during rejection but for both
cellular (26) and antibody-mediated rejection (40, 41). As the
performed blood sample analysis happened long-time after
rejection, the sequestration might continue even in the absence
of clinical rejection symptoms.
Furthermore, composition of NK subsets was more severely
altered in patients who had experienced rejection episodes.
Patients with cellular showed lower total NK cells, and a higher
proportion displayed a more differentiated CD56high phenotype.
This might reflect their rejection-dependent activation and
intragraft accumulation. However, this is contrary to previous
reports which showed reduced circulating NK cells and elevated
proportions of CD56bright NK cells in renal allograft recipients
with DSA and non-DSA anti-HLA mAbs or NK-cell related
transcripts in AMR biopsies (42–44).
Regardless of the time post-transplant or occurrence of
rejections ITx patients displayed increased systemic proportions
of αβ CD4+CD25++Foxp3+ regulatory T cells. The majority
of the Tregs had a CCR4+ activated memory phenotype with
co-expression of predominantly CCR6. Our results question
the conclusions drawn from a recently published study in
which high percentages of Tregs upon intestinal transplantation
were ascribed to a special immunomodulatory protocol and
associated with improved long-term graft function (45). In
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this study, ITx patients receiving the immunomodulatory
protocol were compared to kidney transplant patient groups
and healthy controls but not to ITx patients on other
immunosuppressive medications. Thus, high proportions of
CCR6+ Tregs might rather indicate permanent recruitment
to counterbalance ongoing immune cell activation following
intestinal transplantation.
Our study has some limitations: the patient cohort was
relatively small and no intragraft sampling was performed. In
addition, given the high mortality rate of intestinal transplant
patients within the first years after transplantation, the long-
term groups (ITx1 and ITx2) have a bias toward survivors.
Therefore, it is even more surprising to observe these alterations
in immune cell composition long term after transplantation in
the surviving patients.
Furthermore, this is the first comprehensive assessment
of time-dependent and rejection-dependent alterations of
systemic immune cell composition. Our findings clearly reveal
persistent inflammatory responses and activation of immune
cells upon intestinal transplantation potentially contributing
to unsatisfactory long-term results compared to other solid
organ transplants. In future, it will be important to perform
comparative investigations in other solid organ graft recipients,
but this was clearly beyond the scope of our study.
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